Scott Sacane

#Founder and CEO @CatalyticData. Want to make life sciences R&D go faster. #Biotech, molecular biology, #startups, #SaaS, skiing and big dogs.

[Scott Sacane @ScottSacane]

@AndrewArruda Perfect analogy

[Scott Sacane @ScottSacane]

@venturetwins Gotta fight it on principle! When my daughter was in 6th grade a question on a science test asked Which organelle contains DNA? A) Nucleus B) Mitochondria C) Chloroplast D) None of the above. I emailed the teacher that A, B and C are correct and he replied “don’t be stupid”

[TJ Cradick @NucleaseLab]

Thanks Tyler Menichiello @_CellandGene. Great to share exciting work at @ExcisionBio: advances in multiplex #GeneEditing & programmable nucleases moving us towards a cure for #HIV and other chronic, viral infectious diseases  - #HSV, #HBV and PLM/JCV.
https://t.co/gtLgW0YgEv

[Scott Sacane @ScottSacane]

@jasonlk Truth

[Scott Sacane @ScottSacane]

@evolscientist Straight bullshit.

[Ella Marushchenko @Ella_Maru]

New cover image from Ella Maru Studio! In the tweets below I included description of the cover, sketch from authors and our first draft 🤠

"Peritumoural immunomodulatory scaffolds"

Article: https://t.co/Slq5wKoXCq

#sciart

[Scott Sacane @ScottSacane]

@mhdempsey Labs are automating, biological data digitized and analysis is now in silico. Wave one techbio built walls to protect on prem workflows only to find in 2022 all the best stuff resides outside their walls. Wave two can bypass all that by adopting cloud based platforms to go faster

[Catalytic @CatalyticData]

EGNYTE LIFE SCIENCES SUMMIT is this week: Join Us 👉June 15/ 3:10 - 3:35 pm Life Sciences experts will provide insight + lessons learned for launching successful early-stage companies: Save your spot now 👉 https://t.co/mb5hblJsrO #biotech

[Gary @every_daydad]

I legit do not understand sleep tracking with an Apple Watch.

When are you supposed to charge the watch?

[Scott Sacane @ScottSacane]

@PeterKolchinsky This is a great piece, Peter. Dating myself but I was on the Sell Side when Centocor and Synergen’s phase III sepsis trials failed. Valuations went to levels few believed and very little M&A got done. Boards and Management should pay attention. Investors will do their thing.

[Scott Sacane @ScottSacane]

@bradloncar I’m going to date myself but Imclone was sub $1 pre Erbitux Phase II, IDEC was $1.50 pre-phase II Rituxan, Cephalon $5 post Mytrophin rejection, Alkermes sub $3, and Medimmune < $5 Synagis ODAC rejection

[Scott Sacane @ScottSacane]

This is so true. Leadership in #lifesciences need to understand that #Bioinformatics expertise is not software engineering expertise. Bioinformatics compute on infrastructure built by software engineers. #DataScience

[Vega Shah @dr_alphalyrae]

Most of biotech software problems are at their core, software problems - legacy code, scalability, observability, security, skill gaps etc. But the biotech software workforce and leadership is disproportionately made up of bio experts versus software experts. (1/2)

[BioDecoded @BioDecoded]

Bi-order multimodal integration of single-cell data | Genome Biology
https://t.co/zR4TMSL33l

#Bioinformatics

[Scott Sacane @ScottSacane]

@SahilBloom @sweatystartup Had a similar experience in HS. Couldn’t find the plate and when I did it wasn’t pretty. No pitch count back then! My coach said “focus on making the next pitch.” The lesson I learned and used with my kids was to reward process over outcome. It reframes failure for parent & child

[Scott Sacane @ScottSacane]

@PeterKolchinsky I don’t know why Rxs were’t affected. I was doing work on Alkermes’ long acting formulation, spoke to 6 docs (n not that big) and their perception was the overall profile was best in class. But when I asked they couldn’t cite specific data/studies underpinning that perception.

[Scott Sacane @ScottSacane]

@PeterKolchinsky True. Post launch aripiprazole was shown to be less effective than olanzipine and equivalent to risperidone in head to head RCTs but still dominates the class. Better sedation profile but the disparity in sales is quite large. Inferior efficacy didn’t reduce reward.

[Scott Sacane @ScottSacane]

@PeterKolchinsky Agreed! But RWE post launch doesn’t often change prescribing in a straight line because it’s not clear signal for docs. Reps and company collateral act as a foil. Clear signal and label changes no doubt should and do effect sales. To me, drugs like Abilify are examples.

[Prof. Nikolai Slavov @slavov_n]

Just a periodic reminder:

RNA abundance ≠ transcription activity.

RNA abundance is also regulated by RNA degradation.

[Scott Sacane @ScottSacane]

Really excited to partner with @idtdna to help #researchers better quantify the full array of on- and off-target gene editing events in their data. rhAmpSeq™ is powerful! Our new pipeline https://t.co/QgKL2B5kTF and the PR https://t.co/kgp3ShTTNC #BioIT #Bioinformatics #CRISPR

[Catalytic @CatalyticData]

We're excited to partner with the amazing team @idtdna to bring high throughput rhAmpSeq™ CRISPR data analysis to the life sciences community. Check out our pipeline https://t.co/AQQA5q6aQR and the PR https://t.co/uZpjgUYpLn #lifesciences #bioinformatics #crispr #geneediting